Pharma

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Lilly Alzheimer’s drug adcomm, Amylyx ALS drug flop, and more

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

First Opinion Amit Etkin

STAT Plus: It’s time to rethink everything about our approach to psychiatric drug development

Politics John Wilkerson

STAT Plus: In his State of the Union, Biden takes clear aim at ‘Big Pharma’

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a Lilly obesity-drug ad, a $35 cap on inhalers, and more

The Readout Damian Garde

STAT Plus: Banning WuXi is more complicated than it might sound

Pharmalot Ed Silverman

STAT Plus: Boehringer Ingelheim to cap asthma inhaler out-of-pocket costs at $35

The Readout Damian Garde

STAT Plus: Bayer’s not breaking up. At least not yet

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about HIV drug resistance, march-in rights, and more

Pharmalot Ed Silverman

STAT Plus: WTO proposal for Covid diagnostics and therapeutics waiver is abandoned

The Readout Damian Garde

STAT Plus: Where’s Lilly’s Alzheimer’s approval?

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about Ozempic tackling kidney disease, OTC birth control, and more

Pharma Andrew Joseph

STAT Plus: Novo Nordisk’s diabetes drug Ozempic cuts risk of kidney disease progression, trial shows

Pharmalot Ed Silverman

STAT Plus: White House is told the big three PBMs are ‘everything wrong with this industry’

The Readout Meghana Keshavan

STAT Plus: Serum Institute of India wants government HPV contract

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about a nixed Medicare negotiation lawsuit, an Obamacare challenge, and more

First Opinion Paul Shay

STAT Plus: Missing data is making it difficult for the pharmaceutical industry to help LGBTQ+ people

Pharmalot Ed Silverman

STAT Plus: Many costly generic drugs are unavailable at Amazon, Cuban, and other alternative pharmacies

Politics Rachel Cohrs

STAT Plus: Federal judge rules against AstraZeneca in lawsuit challenging Medicare drug price negotiation

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about RSV vax link to GSB, a Pfizer donation, and more

The Readout Meghana Keshavan

STAT Plus: Despite good data, Ironwood’s shares plummet 

Politics John Wilkerson

STAT Plus: What does America’s crackdown on Chinese firms mean for the U.S. biotech sector?

The Readout Damian Garde

STAT Plus: The next act for a biotech rainmaker

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: We’re reading about White House eyeing PBMs, Pfizer CEO’s frustrations, and more

Health tech Mario Aguilar

STAT Plus: Icon acquires HumanFirst to boost support for digital tools in clinical trials

Pharma Matthew Herper

STAT Plus: Pfizer is about to make a big push in cancer. Will investors listen?

Pharma Elaine Chen

STAT Plus: A ‘vaccine-like’ version of Wegovy is on the drawing board at Novo Nordisk

Exclusive Ed Silverman

STAT Plus: White House to hold a listening session on reforming pharmacy benefit managers